new version V2017

CDK (cyclin-dependent kinase) inhibitor
Description Results

Abemaciclib - Palbociclib - Ribociclib      

  • Group by...

TrialStudied treatmentControl treatmentpatientsROBResultNCT

advanced breast cancer (metastatic)

abemaciclib
MONARCH 3, 2017Abemaciclib +nsAInsAI Low risk of bias ConclusiveNCT02246621
palbociclib
PALOMA 3, 2015palbociclib + fulvestrantfulvestrant alone2nd line Low risk of bias ConclusiveNCT01942135
PALOMA 1/TRIO-18, 2015palbociclib + letrozoleletrozole alone Exploratory SuggestingNCT00721409
PALOMA-2, 2016palbociclib + letrozoleletrozole alonefirst line Low risk of bias ConclusiveNCT01740427
PEARL ongoing palbociclib + exemestanecapecitabine Risk of bias - NCT02028507
PALOMA-4 ongoing palbociclib + letrozoleletrozole alone Low risk of bias - NCT02297438
PENELOPE-B ongoing palbociclibplacebo Low risk of bias - NCT01864746
ribociclib
MONALEESA-2, 2016ribociclib (LEE011) + letrozoleletrozole alonefirst line Low risk of bias ConclusiveNCT01958021
MONALEESA-7 ongoing ribociclib (LEE011) + nsAI/TAM gosnsAI/TAM + gos Low risk of bias - NCT02278120
MONALEESA-3 ongoing ribociclib (LEE011)+ fulvestrantfulvestrant alone Low risk of bias - NCT02422615

lung cancer (metastatic)

abemaciclib
JUNIPER, 2018abemacicliberlotinib2nd line Risk of bias - NCT02152631



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons